Multiple Myeloma: all 3,712 studies
Page 22 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple MyelomaWithdrawnNCT04466475Phase 1
- HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell TransplantationWithdrawnNCT04464889Phase 1
- A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)CompletedNCT04458831
- Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple MyelomaNo longer availableNCT04453397
- Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple MyelomaNo longer availableNCT04452994
- Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04447573Not applicable
- Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT04445701Phase 1/2
- Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
- Digital Life Coaching for Myeloma Patients Undergoing TransplantationCompletedNCT04432818Not applicable
- A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MMStatus unknownNCT04412889Early Phase 1
- Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell TherapyCompletedNCT04409314
- Tasquinimod for the Treatment of Relapsed or Refractory MyelomaTerminatedNCT04405167Phase 1
- A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic FunctionWithdrawnNCT04398680Phase 1
- A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT04398485Phase 1
- A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04394650Phase 1
- eHealth for the ElderlyCompletedNCT04393090
- Iberdomide Combined With Low-dose Cyclophosphamide and DexamethasoneActive, not recruitingNCT04392037Phase 2
- Multiple Myeloma (MM) Quality of Life (QOL) StudyStatus unknownNCT04388735
- Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma PatientsCompletedNCT04379817Phase 2
- Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple MyelomaStatus unknownNCT04376957Not applicable
- CTFEA Myeloma StudyStatus unknownNCT04364724
- Muscle Stimulation for Physical Function During Stem Cell TransplantCompletedNCT04364256Not applicable
- Study of Dara-Pembro for Multiple Myeloma PatientsWithdrawnNCT04361851Phase 2
- INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple MyelomaWithdrawnNCT04355039Phase 1
- COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompletedNCT04354246Phase 1
- Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney FailureTerminatedNCT04352205Phase 2
- Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma PatientsWithdrawnNCT04348006Phase 4
- A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaCompletedNCT04322292Phase 1
- BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple MyelomaTerminatedNCT04318327Phase 1
- National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
- Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.Active, not recruitingNCT04309981Phase 1/2
- Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer TreatmentCompletedNCT04309942Not applicable
- Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaStatus unknownNCT04309084Phase 1
- The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma PatientsCompletedNCT04303091Not applicable
- The Feasibility and Effects of Exercise on Patients Suffering From Multiple MyelomaSuspendedNCT04300335Not applicable
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT04295018Phase 1
- Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple MyelomaWithdrawnNCT04288765Phase 3
- Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04287855Phase 2
- Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) PatientsStatus unknownNCT04287660Phase 3
- DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic CancerCompletedNCT04282343Not applicable
- Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT04280328Phase 1
- Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT04277845Phase 2
- A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 CapsuleStatus unknownNCT04275583Phase 1
- Bone Pain in Multiple Myeloma- a Translational StudyStatus unknownNCT04273425
- Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple MyelomaStatus unknownNCT04272151Phase 1/2
- Effect of Sleep Quality on Hematopoietic Cell Transplant Patient OutcomesTerminatedNCT04271930Not applicable
- Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple MyelomaActive, not recruitingNCT04270409Phase 3
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaActive, not recruitingNCT04268498Phase 2
- Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.Status unknownNCT04260490
- A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTEWithdrawnNCT04258683Phase 2
- Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple MyelomaCompletedNCT04248244Not applicable
- A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT04244656Phase 1
- Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and BortezomibTerminatedNCT04243109Phase 2
- The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral BloodTerminatedNCT04242121
- Rehabilitation Needs of the Malaysian Haematological Cancer SurvivorsCompletedNCT04236063
- BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple MyelomaStatus unknownNCT04236011Early Phase 1
- Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple MyelomaWithdrawnNCT04230031Phase 2
- Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction TherapyWithdrawnNCT04223661Phase 2
- Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative RemissionActive, not recruitingNCT04221178
- Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM PatientsCompletedNCT04217967Phase 4
- A Study of AZD0466 in Patients With Advanced Hematologic or Solid TumorsTerminatedNCT04214093Phase 1
- Amplification of Zinc Finger Protein 217 Gene in Multiple MyelomaStatus unknownNCT04212858Not applicable
- A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)CompletedNCT04196491Phase 1
- Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple MyelomaStatus unknownNCT04194931Phase 1
- Treatment of Hematological Malignancy With Novel CAR-T Cells.Status unknownNCT04191941Early Phase 1
- Determining Normal Range for Free Light Chains in Serum Among TwinsCompletedNCT04191057Not applicable
- Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple MyelomaStatus unknownNCT04186052Early Phase 1
- Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)Active, not recruitingNCT04184050Phase 1
- A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaStatus unknownNCT04182581Early Phase 1
- A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple MyelomaTerminatedNCT04178902Phase 1
- Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMActive, not recruitingNCT04176718Phase 2
- RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple MyelomaCompletedNCT04176380Phase 2
- A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaActive, not recruitingNCT04174196Phase 2
- A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT04171843Phase 1
- Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseaseActive, not recruitingNCT04166565Phase 2
- Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT04163107Phase 1
- Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple MyelomaStatus unknownNCT04162119Phase 2
- BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple MyelomaStatus unknownNCT04156269Early Phase 1
- Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaActive, not recruitingNCT04155749Phase 1
- VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple MyelomaCompletedNCT04151615
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITTerminatedNCT04150965Phase 1/2
- Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple MyelomaWithdrawnNCT04150692Phase 2
- A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on PanobinostatCompletedNCT04150289
- Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.Active, not recruitingNCT04144387Not applicable
- Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)TerminatedNCT04142619Phase 1
- Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease ProgressionCompletedNCT04137523
- NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaCompletedNCT04136756Phase 1
- A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)CompletedNCT04135963
- Immune Profiling in Multiple MyelomaCompletedNCT04135079
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaActive, not recruitingNCT04133636Phase 2
- A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma PatientsActive, not recruitingNCT04124497Phase 2
- A Study of WVT078 in Patients With Multiple Myeloma (MM)TerminatedNCT04123418Phase 1
- Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple MyelomaStatus unknownNCT04122092
- A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Phase 1
- Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine CareTerminatedNCT04111809
- Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma PatientsActive, not recruitingNCT04108624Not applicable
- A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaActive, not recruitingNCT04108195Phase 1
- Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDsTerminatedNCT04106700Phase 2
- Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple MyelomaCompletedNCT04100044Not applicable